Dexcom Intrinsic Value Calculator – DEXCOM Receives Positive Rating from Brokerages, Rated ‘Moderate Buy’
January 6, 2024
☀️Trending News
DEXCOM ($NASDAQ:DXCM): DexCom, Inc. is a medical device company that specializes in continuous glucose monitoring systems. Recently, the company has been given a consensus rating of “Moderate Buy” by brokerages. The Moderate Buy rating given to DexCom is a sign that the company is performing well and is expected to have a strong future. With its continuous glucose monitoring systems, DexCom has become a leader in diabetes care, playing a crucial role in helping individuals manage their condition.
The positive rating from brokerages reflects this success and will likely give investors more confidence in the stock. Overall, the Moderate Buy rating given to DexCom shows that the company is doing well and is expected to continue its strong performance in the future. Investors should consider this rating when deciding whether or not to invest in the stock.
Stock Price
On Tuesday, DEXCOM stock was given a positive rating from several brokerages, with the consensus being a “Moderate Buy”. At the close of trading, the stock opened at $123.2 and closed at $123.1, representing a decrease of 0.8% from its previous closing price of $124.1. This rating from brokerages is a positive sign for the future of the company, and should act as reassurance to any investors who are considering buying shares in the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dexcom. DEXCOM_Receives_Positive_Rating_from_Brokerages_Rated_Moderate_Buy”>More…
| Total Revenues | Net Income | Net Margin |
| 3.4k | 377 | 11.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dexcom. DEXCOM_Receives_Positive_Rating_from_Brokerages_Rated_Moderate_Buy”>More…
| Operations | Investing | Financing |
| 747.4 | -1.12k | 312.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dexcom. DEXCOM_Receives_Positive_Rating_from_Brokerages_Rated_Moderate_Buy”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.6k | 4.33k | 5.87 |
Key Ratios Snapshot
Some of the financial key ratios for Dexcom are shown below. DEXCOM_Receives_Positive_Rating_from_Brokerages_Rated_Moderate_Buy”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.2% | 19.5% | 18.1% |
| FCF Margin | ROE | ROA |
| 14.7% | 17.7% | 5.9% |
Analysis – Dexcom Intrinsic Value Calculator
At GoodWhale, we recently completed an analysis of DEXCOM‘s fundamentals. Our proprietary Valuation Line tool suggests that the fair value of DEXCOM share is around $139.9. Unfortunately, the stock is currently trading at $123.1, which is a fair price undervalued by 12.0%. We believe that this presents a great opportunity for investors to capitalize on the stock’s significant discount from its fair value. More…
Peers
The company was founded in 1999 and is headquartered in San Diego, California. DexCom has a market cap of $15.8 billion as of May 2020. The company’s competitors include Abbott Laboratories, Insulet Corp, and Medtronic PLC.
– Abbott Laboratories ($NYSE:ABT)
Abbott Laboratories is a publicly traded healthcare company with a market capitalization of $173.42 billion as of 2022. The company’s return on equity is 16.7%. Abbott Laboratories is a diversified healthcare company that develops and manufactures a wide range of products and services for the treatment of various medical conditions. The company’s product portfolio includes pharmaceuticals, diagnostics, medical devices, and nutritional products. Abbott Laboratories has a strong presence in both developed and emerging markets.
– Insulet Corp ($NASDAQ:PODD)
Insulet Corporation is a medical device company that manufactures and sells insulin delivery systems for people with diabetes. The company was founded in 2000 and is headquartered in Massachusetts, United States. Insulet Corporation has a market capitalization of 20.48 billion as of 2022 and a return on equity of 8.72%. The company’s products include the OmniPod insulin pump, the PodderPrep insulin pump starter kit, and the mylife Pods insulin pump cartridges.
– Medtronic PLC ($NYSE:MDT)
Medtronic PLC is a medical device company that focuses on providing treatments for cardiovascular diseases, diabetes, and neurological disorders, among others. As of 2022, the company has a market cap of 105.39B and a return on equity of 7.49%. Medtronic PLC is headquartered in Dublin, Ireland.
Summary
Investment analysis of DexCom, Inc. shows that the majority of brokerages have given the company a “Moderate Buy” rating. This indicates that brokerages consider it a safe-to-moderate investment for those looking to increase their portfolio. DexCom is a medical device company that produces glucose monitoring systems for people with diabetes.
Analysts expect the stock to continue growing, thanks to their innovative technological advancements in the health care industry. Analysts suggest that investors should add some shares of DexCom to their portfolio if they are looking for a steady growth in value over time.
